Doug Cole

Managing Partner at Flagship Pioneering

Doug Cole

Doug Cole

Managing Partner at Flagship Pioneering

Overview
Career Highlights

Flagship Pioneering
Sigilon Therapeutics, Inc.
Inzen Therapeutics

RelSci Relationships

2806

Number of Boards

35

Birthday

1961

Age

60

Relationships
RelSci Relationships are individuals Doug Cole likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Moderna, Inc.

Relationship likelihood: Strong

Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Director & Chief Executive Officer at Moderna, Inc.

Relationship likelihood: Strong

Co-Founder at Vir Biotechnology, Inc.

Relationship likelihood: Strong

Founder at Fate Therapeutics, Inc.

Relationship likelihood: Strong

Chairman of the Board, Co-Founder at Concert Pharmaceuticals, Inc.

Relationship likelihood: Strong

Professor at Harvard University

Relationship likelihood: Strong

Co-Founder at Moderna, Inc.

Relationship likelihood: Strong

President at Epiva Biosciences, Inc.

Relationship likelihood: Strong

Co-Founder at Flagship Pioneering

Relationship likelihood: Strong

Paths to Doug Cole
Potential Connections via
Relationship Science
You
Doug Cole
Managing Partner at Flagship Pioneering
Education
MD
Class of 1986

The University of Pennsylvania is the oldest and one of the finest medical schools in the United States. Penn is rich in tradition and heritage and at the same time consistently at the forefront of new developments and innovations in medical education and research. Since its founding in 1765 the School has been a strong presence in the community and prides itself on educating the leaders of tomorrow in patient care, biomedical research, and medical education. At Penn academic excellence, as well as compassion for the patients we are privileged to serve, are stressed. Skillful compassion is truly a hallmark of the Penn learning experience. The Perelman School of Medicine at the University of Pennsylvania consistently ranks among the top five in US News and World Report’s rankings of research-oriented medical schools.

AB
Class of 1982

Founded in 1769, Dartmouth is a member of the Ivy League and consistently ranks among the world's greatest academic institutions. Dartmouth has forged a singular identity for combining its deep commitment to outstanding undergraduate liberal arts and graduate education with distinguished research and scholarship in the Arts & Sciences and its three leading professional schools—the Geisel School of Medicine, Thayer School of Engineering, and the Tuck School of Business.

Memberships
Member
Current

Alpha Omega Alpha supports many programs for medical students and physicians at our 123 chapters, and publishes a quarterly journal, The Pharos, which contains articles on nontechnical medical subjects, including history, ethics, national issues, personal essays, and poetry.

Career History
Professional
Prior

Hypnion, Inc. discovered and developed neuroscience drugs. It focused on the development of novel therapeutics for the treatment of central nervous system disorders to serve the underserved markets of sleep and wake-alertness disorders and circadian rhythm abnormalities. The company was founded in 2000 and was headquartered in Lexington, MA.

Managing Partner
2001 - Current

Flagship Pioneering seeks investment opportunities in companies located globally. The firm focuses on companies operating in the fields of therapeutics, life science tools & diagnostics, and bioenergy or cleantech. It provides financing for seed, early, and later-stage capital requirements. It acts as a lead investor. It also makes co-investments.

Co-Founder
2004 - Prior

Ensemble Therapeutics Corp. develops novel classes of therapeutics and bioassays for research and diagnostics. The firm focuses on the discovery and development of breakthrough small molecule therapies for patients with cancer and other serious diseases. The company was founded by Douglas G. Cole, Noubar B. Afeyan and David R. Liu in 2004 and is headquartered in Cambridge, MA.

Boards & Committees
Member, Board of Directors
2020 - Current

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses in identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 13, 2018 and is headquartered in Seattle, WA.

Member, Board of Directors
2015 - Current

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Director
2015 - Current

Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA.

Member, Board of Directors
Current

Spinal Muscular Atrophy Foundation is a nonprofit company headquartered in New York, NY, that provides spinal muscular atrophy healthcare services.The company says this about itself: Founded in 2003, the SMA Foundation is a nonprofit organization dedicated to accelerating the development of treatments for SMA through targeted funding of clinical research and novel drug development efforts. Since its inception, the Foundation has awarded ~$150 million for SMA research. In addition, the Foundation is committed to raising awareness and generating support for increased research efforts in SMA among the leaders of industry and government. When the SMA Foundation was founded, there were no treatments for SMA available. Today there are two approved treatments and several more in clinical and preclinical development.

Member, Board of Directors
Prior

TRADITIONAL SUMMER CAMP FOR BOYS AGES 7 - 15

Member, Genetics Advisory Council
Tenure Unconfirmed
Political Donations
$500
2002

Senator at Office of the Senator from Utah, Mitt Romney

$200
2002

Co-Founder at Empower Schools

Investments
Details Hidden

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Details Hidden

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Details Hidden

Ensemble Therapeutics Corp. develops novel classes of therapeutics and bioassays for research and diagnostics. The firm focuses on the discovery and development of breakthrough small molecule therapies for patients with cancer and other serious diseases. The company was founded by Douglas G. Cole, Noubar B. Afeyan and David R. Liu in 2004 and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Doug Cole. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Doug Cole's profile does not indicate a business or promotional relationship of any kind between RelSci and Doug Cole.